The efficacy and safety of sulindac (400 mg vs 600 mg daily) in rheumatoid arthritis. A Canadian Multicentre Study.
Sulindac, an indene derivative of indomethacin, was compared at 2 dosages (400 mg and 600 mg daily) in patients with rheumatoid arthritis. One hundred sixty-two patients from 19 centers completed the study--85 in the low dose group and 77 in the high dose. No difference in efficacy was found between these 2 regimens. Overall adverse reactions were more frequent with the high dose group especially with respect to blood chemistry and gastrointestinal reactions.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001774:Blood Chemical Analysis; D002986:Clinical Trials as Topic; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007192:Indenes / Q000008:administration & dosage*; D008875:Middle Aged; D013467:Sulindac / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D007192:Indenes; D013467:Sulindac